Chronic myelogenous leukemia - Progress at the M. D. Anderson Cancer Center over the past two decades and future directions: First Emil J Freireich Award Lecture

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2723-2733

  Kantarjian, Hagop M ^a,b   Talpaz, Moshe ^a   O'Brien, Susan ^a   Kurzrock, Razelle ^a   Gutterman, Jordan ^a   Keating, Michael J ^a   McCredie, Kenneth B ^a   Freireich, Emil J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Box 61 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; HYDROXYUREA; RETINOIC ACID; STEROID; TOPOTECAN; VINCRISTINE;

CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DATA BASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMAL RESIDUAL DISEASE; ORAL DRUG ADMINISTRATION; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; AWARDS AND PRIZES; CANCER CARE FACILITIES; DATABASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MEDICAL ONCOLOGY; TEXAS; UNITED STATES;

EID: 0031426987     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (101)

1. Kantarjian, H. M., O'Brien, S., Anderlini, P., and Talpaz, M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood, 87: 3069-3081, 1996.
2. Kantarjian, H., Deisseroth, A., Kurzrock, L. R., Estrov, Z., and Talpaz, M. Chronic myelogenous leukemia: a concise update. Blood, 82: 691-703, 1993.
3. Kurzrock, R., Gutterman, J. U., and Talpaz, M. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 319: 990-993, 1988.
4. Cortes, J. E., Talpaz, M., and Kantarjian, M. Chronic myelogenous leukemia: a review. Am. J. Med., 100: 555-570, 1996.
5. Kantarjian, H. M., Keating, M. J., Walters, R. S., McCredie, K. B., Smith, T. L., Talpaz, M., Beran, M., Cork, A., Trujillo, J. M., and Freireich, E. J. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer (Phila.), 58: 2023-2030, 1986.
6. Kurzrock, R., Blick, M. B., Talpaz, M., Velasquez, W. S., Trujillo, J. M., Kouttab, N. M., Kloetzer, W. S., Arlinghaus, R. B., and Gutterman, J. U. Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. Ann. Intern. Med., 105: 673-679, 1986.
7. Shtalrid, M., Talpaz, M., Blick, M., Kantarjian, H., Romero, P., Taylor, K., Walters, R., Schachner, J., and Gutterman, J. Philadelphia-negative chronic myelogenous leukemia with bcr rearrangement: molecular analysis and clinical characteristics. J. Clin. Oncol., 6: 1569-1575, 1988.
8. Kantarjian, H. M., Shtalrid, M., Kurzrock, R., Blick, M., Dalton, W. T., LeMaistre, A., Stass, S. A., McCredie, K. B., Gutterman, J., Freireich, E. J, and Talpaz, M. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am. J. Med., 85: 639-644, 1988.
9. Kurzrock, R., Kantarjian, H. M., Shtalrid, M., Gutterman, J. U., and Talpaz, M. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood, 75: 445-452, 1990.
10. Kantarjian, H., Kurzrock, R., and Talpaz, M. Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. In: C. P. Canellos (ed.), Hematology/Oncology Clinics of North America, Vol. 4, pp. 389-404. Philadelphia: W. B. Saunders Co., 1990.
11. Cortes, J. E., Talpaz, M., Beran, M., O'Brien, S. M., Rios, M-B., Stass, S., and Kantarjian, H. M. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Cancer (Phila.), 75: 464-470, 1995.
12. Kantarjian, H. M., Smith, T. L., McCredie, K. B., Keating, M. J., Walters, R. S., Talpaz, M., Hester, J. P., Bligham, G., Gehan, E., and Freireich, E. J. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood, 66: 1326-1335, 1985.
13. Kantarjian, H. M., Keating, M. J., Smith, T. L., Talpaz, M., and McCredie, K. B. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am. J. Med., 88: 1-8, 1990.
14. Kantarjian, H. M., Smith, T. L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M., and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α. Ann. Intern. Med., 122: 254-261, 1995.
15. Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J. M., and Gutterman, J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Intern. Med., 114: 532-538, 1991.
16. Dekmezian, R., Kantarjian, H. M., Keating, M. J., Talpaz, M., McCredie, K. B., and Freireich, E. J. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer (Phila.), 59: 1739-1743, 1987.
17. Kantarjian, H. M., Talpaz, M., and Gutterman, J. U. Chronic myelogenous leukemia-post, present and future. Hematol. Pathol., 2: 91-120, 1988.
18. Kantarjian, H. M., and Talpaz, M. Definition of the accelerated phase of chronic myelogenous leukemia. J. Clin. Oncol., 6: 180-182, 1988.
19. Talpaz, M., Kantarjian, H., McCredie, K. B., Keating, M. J., and Gutterman, J. U. Chronic myelogenous leukemia: hematologic remissions and cytogenetic improvements induced by recombinant alpha A interferon. N. Engl. J. Med., 314: 1065-1069, 1986.
20. Kantarjian, H. M., Keating, M. J., Estey, E. H., O'Brien, S., Pierce, S., Beran, M., Koller, C., Feldman, E., and Talpaz, M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with alpha interferon and low-dose 1-β-D-arabinofuranosylcytosine. J. Clin. Oncol., 10: 772-778, 1992.
21. Kantarjian, H., O'Brien, S., Beran, M., Koller, C., Andreeff, M., Rios, M-B., Keating, M., Freireich, E., and Talpaz, M. Interferon alpha and low-dose 1-β-D-arabinofuranosylcytosine therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia. Blood, 86: 2105, 1995.
22. O'Brien, S., Kantarjian, H., Keating, M., Beran, M., Koller, C., Robertson, L. E., Hester, J., Rios, M-B., Andreeff, M., and Talpaz, M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood, 86: 3322-3326, 1995.
23. O'Brien, S., Kantarjian, H., Feldman, E., Andreeff, M., Keating, M., Koller, C., Hester, J., Rios, M-B., and Talpaz, M. Sequential homoharringtonine and interferon produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive chronic myelogenous leukemia. Am. Soc. Clin. Oncol., 14: 1006, 1995.
24. Kantarjian, H. M., Keating, M. J., Talpaz, M., Walters, R. S., Smith, T. L., Cork, A., McCredie, K. B., and Freireich, E. J. Chronic myelogenous leukemia in blast crisis: an analysis of 242 patients. Am. J. Med., 83: 445-454, 1987.
25. Terjanian, T., Kantarjian, H., Keating, M., Talpaz, M., McCredie, K., and Freireich, E. J. Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer (Phila.), 59: 297-300, 1987.
26. Iacoboni, S. J., Plunkett, W. K., Kantarjian, H., Estey, E., Keating, M. J., McCredie, K. B., and Freireich, E. J. High dose 1-β-D-arabinofuranosylcytosine: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J. Clin. Oncol., 4: 1079-1088, 1986.
27. Kantarjian, H. M., Walters, R. S., Keating, M. J., Talpaz, M., Andersson, B., Beran, M., McCredie, K. B., and Freireich, E. J. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose 1-β-D-arabinofuranosylcytosine. Cancer (Phila.), 62: 672-676, 1988.
28. Kantarjian, H. M., Talpaz, M., Hester, J., Feldman, E., Korbling, M., Liang, J., Rios, M-B., Smith, T. L., Calvert, L., and Deisseroth, A. B. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J. Clin. Oncol., 13: 553-559, 1995.
29. Kantarjian, H., Talpaz, M., Kontoyiannis, D., Gutterman, J., Keating, M. J., Estey, E. H., O'Brien, S., Rios, M-B., Beran, M., and Deisseroth, A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol., 10: 398-405, 1992.
30. Walters, R. S., Kantarjian, H. M., Keating, M. J., Talpaz, M., Childs, C. C., McCredie, K. B., and Freireich, E. J. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and Adriamycin infusion plus high-dose decadron (VAD). Cancer (Phila.), 60: 1708-1712, 1987.
31. Derderian, P. M., Kantarjian, H. M., Talpaz, M., O'Brien, S., Cork, A., Estey, E., Pierce, S., and Keating, M. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am. J. Med., 94: 69-74, 1993.
32. Kantarjian, H. M., Dixon, D., Keating, M. J., Talpaz, M., Walters, R. S., McCredie, K. B., and Freireich, E. J. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (Phila.), 61: 1441-1446, 1988.
33. Majlis, A., Smith, T. L., Talpaz, M., O'Brien, S., Rios, M-B., and Kantarjian, H. M. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J. Clin. Oncol., 14: 195-203, 1996.
34. Cortes, J., Kantarjian, H., O'Brien, S., Beran, M., Estey, E., Koller, C., Andreeff, M., Kornblau, S., Keating, M., Freireich, E. J., and Talpaz, M. Suppression of clonal evolution in patients with Philadelphia chromosome-positive chronic myelogenous leukemia on interferon-alpha therapy. Blood, 88 (Suppl. 1): 232a, 1996.
35. Yoffe, G., Blick, M., Kantarjian, H., Spitzer, G., Gutterman, J., and Talpaz, M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood, 69: 961-963, 1987.
36. Claxton, D., Deisseroth, A., Talpaz, M., Reading, C., Kantarjian, H., Trujillo, J., Stass, S., Gooch, G., and Spitzer, G. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood, 79: 997-1002, 1992.
37. Kantarjian, H. M., Vellekoop, L., McCredie, K. B., Keating, M. J., Hester, J., Smith, T., Barlogie, B., Trujillo, J., and Freireich, E. J. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J. Clin. Oncol., 3: 192-200, 1985.
38. Kantarjian, H. M., Talpaz, M., Keating, M. J., Estey, E. H., O'Brien, S., Beran, M., McCredie, K. B., Gutterman, J., and Freireich, E. J. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer (Phila.), 68: 1201-1207, 1991.
39. Vellekoop, L., Zander, A. R., Kantarjian, H. M., Jagannath, S., Hester, J. P., Trujillo, J., McCredie, K. B., Zagars, G., Spitzer, G., and Dicke, K. A. Piperazinedione, total body irradiation and autologous bone marrow transplantation in chronic myelogenous leukemia. J. Clin. Oncol., 4: 906-911, 1986.
40. Kantarjian, H. M., Talpaz, M., LeMaistre, C. F., Spinolo, J., Spitzer, G., Yau, J., Dicke, K., Jagannath, S., and Deisseroth, A. B. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer (Phila.), 2959-2965, 1991.
41. Kantarjian, H. M., Talpaz, M., Andersson, B., Khouri, I., Giralt, S., Rios, M. B., Champlin, R., Hester, J., and Deisseroth, A. B. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant., 14: 57-61, 1994.
42. Khouri, I., Kantarjian, H. M., Talpaz, M., Giralt, S., Rios, M. O., Hester, J. P., Champlin, R. E., and Deisseroth, A. B. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant., 17: 775-779, 1996.
43. Carella, A. M., Podesta, M., Frassoni, F., et al. Collection of "normal" blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant., 12: 267-271, 1993.
44. Kantarjian, H. M., Talpaz, M., Hester, J., Feldman, E., Korbling, M., Liang, J., Rios, M-B., Smith, T. L., Calvert, L., and Deisseroth, A. B. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J. Clin. Oncol., 13: 553-559, 1995.
45. Talpaz, M., Kantarjian, H., Liang, J., Calvert, L., Hamer, J., Tibbits, P., Durett, A., Claxton, D., Giralt, S., Khouri, I., Przepiorka, D., van Besien, K., Andersson, B., Mehra, R., Gajewski, J., Seong, D., Hester, J., Estey, E., Korbling, M., Pollicardo, N., Berenson, R., Heimfeld, S., Champlin, R., and Deisseroth, A. B. Percentage of Philadelphia chromosome Ph-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood, 85: 3257-3263, 1995.
46. Deisseroth, A. B., Kantarjian, H., Talpaz, M., Champlin, R., Reading, C., Andersson, B., and Claxton, D. Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. Hum. Gene Ther., 4: 71-85, 1993.
47. Deisseroth, A. B., Zu, Z., Claxton, D., et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood, 83: 3068-3076, 1994.
48. Talpaz, M., Kantarjian, H. M., McCredie, K. B., Keating, M. J., Trujillo, J., and Gutterman, J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood, 69: 1280-1288, 1987.
49. Talpaz, M., McCredie, K., Kantarjian, H., Trujillo, J., Keating, M., and Gutterman, J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br. J. Haematol., 64: 87-94, 1986.
50. Talpaz, M., Kurzrock, R., Kantarjian, H., Rothberg, J., Saks, S., Evans, L., and Gutterman, J. U. A Phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer (Phila.), 68: 2125-2130, 1991.
51. Talpaz, M., Plager, C., Quesada, J., Benjamin, R. S., Kantarjian, H. M., and Gutterman, J. U. Difluromethylornithine-leukocyte interferon: a Phase I study in cancer patients. Eur. J. Cancer Clin. Oncol., 22: 685-689, 1986.
52. Wilhelm, M., Ramos, C. M., O'Brien, S., Pierce, S., Keating, M., Talpaz, M., and Kantarjian, H. M. Effect of alpha-interferon therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia (Baltimore), in press, 1997.
53. Giralt, S. A., Kantarjian, H. M., Talpaz, M., Riso, M-G., Del Giglio, A., Andersson, B. S., Przepiorka, A., Deisseroth, A. B., and Champlin, R. E. Effect of prior interferon alpha therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J. Clin. Oncol., 11: 1055-1061, 1993.
54. Cortes, J., Kantarjian, H., O'Brien, S., and Talpaz, M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Blood, 88 (Suppl. 1): 232, 1996.
55. O'Brien, S., Keating, A., Kantarjian, H., Talpaz, M., Beran, M., Stass, S., Rios, M., and Plunkett, W. Homoharringtonine induces apoptosis in chronic myelogenous leukemia cells. Blood, 82: 2203, 1993.
56. Kantarjian, H., O'Brien, S., Keating, M., Beran, M., Koller, C., Keating, M., Estey, E., Kornblau, S., Rios, M-B., and Talpaz, M. Homoharringtonine and low-dose 1-β-D-arabinofuranosylcytosine combination therapy has significant activity in patients with late phase Philadelphia chromosome positive chronic myelogenous leukemia. Blood, 88 (Suppl. 1): 578a, 1996.
57. Kantarjian, H. M., O'Brien, S. M., Keating, M., Beran, M., Estey, E., Giralt, S., Rios, M-B., de Vos, D., and Talpaz, M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia, 11: 1617-1620, 1997.
58. Anzai, H., Frost, P., and Abbrussese, J. L. Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res., 52: 2180-2185, 1992.
59. Giralt, S., Davis, M., O'Brien, S., van Besien, K., Champlin, R., de Vos, D., and Kantarjian, H. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 11 (Suppl. 1): S32-S34, 1997.
60. Beran, M., Kantarjian, H., O'Brien, S., Koller, C., Albitar, M., Arbuck, S., Pierce, S., Moore, M., Abbruzzese, J. L., Andreeff, M., Keating, M., and Estey, E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 88: 2473-2479, 1996.
61. Meyskens, F. K., Kopecky, K. J., Appelbaum, F. R., Balcerzak, S. P., Samlowski, W., and Hynes, H. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leukemia Res., 19: 605-612, 1995.
62. Cortes, J., Kantarjian, H., O'Brien, S., Beran, M., Keating, M., and Talpaz, M. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia, 11: 929-932, 1997.
63. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H., and Champlin, R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89: 4531-4536, 1997.
64. 1 positive chronic myelogenous leukemia. Blood, 72: 485-490, 1988.
65. Verschraegen, C. F., Kantarjian, H. M., Hirsch-Ginsberg, C., Lee, M. S., O'Brien, S., Rios, M-B., Stass, S. A., and Keating, M. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer (Phila.), 76: 992-997, 1995.
66. Lee, M., Chang, K., Freireich, E. J, Kantarjian, H., Talpaz, M., Trujillo, J. M., and Stass, S. A. Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood, 72: 893-897, 1988.
67. Lee, M-S., LeMaistre, A., Kantarjian, H. M., Talpaz, M., Freireich, E. J, Trujillo, J. M., and Stass, S. A. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood, 73: 2165-2170, 1989.
68. Verschraegen, C. F., Talpaz, M., Hirsch-Ginsberg, C. F., Pherwani, L. R., Rios, M-B., Stass, S. A., and Kantarjian, H. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood, 85: 2705-2710, 1995.
69. Kloetzer, W., Kurzrock, R., Smith, L., et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology, 140: 230-238, 1985.
70. Wetzler, M., Talpaz, M., Van Etten, R. A., Hirsh-Ginsberg, C., Beran, M., and Kurzrock, R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J. Clin. Invest., 92: 1925-1939, 1993.
71. Wetzler, M., Talpaz, M., Yee, G., Stass, S. A., Van Etten, R. A., Andreeff, M., Goodacre, A. M., Kleine, H. D., Mahadevia, R. K., and Kurzrock, R. Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. Proc. Natl. Acad. Sci. USA, 92: 3488-3492, 1995.
72. Talpaz, M., Estrov, Z., Kantarjian, H., Ku, S., Foteh, A., and Kurzrock, R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. J. Clin. Invest., 94: 1383-1389, 1994.
73. Kurzrock, R., Shtalrid, M., Romero, P., et al. A novel c-abl protein in Philadelphia positive acute lymphoblastic leukemia. Nature (Lond.), 325: 635-637, 1987.
74. Kantarjian, H., Talpaz, M., Estey, E., Ku, S., and Kurzrock, R. What is the contribution of molecular studies to the diagnosis of bcr-abl positive disease in adult acute leukemia? Am. J. Med., 96: 133, 1994.
75. Kantarjian, H. M., Talpaz, M., Dhingra, K., Estey, E., Keating, M. J., Ku, S., Stass, S., and Kurzrock, R. Significance of the p210 versus p190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood, 78: 2411-2418, 1991.
76. BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. Leukemia (Baltimore), 5: 191-195, 1991.
77. Guo, J. Q., Wang, J. Y. J., and Arlinghaus, R. B. Detection of bcr-abl proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res., 57: 3048-3051, 1991.
78. Guo, J. Q., Hirsch-Ginsberg, C. F., Xian, Y. M., Stass, S. A., Champlin, R. E., Giratt, S. E., McCredie, K. B., Campbell, M. L., and Arlinghaus, R. B. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia. Hematol. Pathol., 7: 91-106, 1993.
79. Qiang, J. G., Lian, J., Glassman, A., Talpaz, M., Kantarjian, H., Deisseroth, A. B., and Arlinghaus, R. B. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am. J. Clin. Pathol., 106: 442-448, 1996.
80. Guo, J. Q., Lian, J. Y., Xian, Y. M., Lee, M. S., Deisseroth, A. B., Stass, S. A., Champlin, R. E., Talpaz, M., Wang, J. Y., and Arlinghaus, R. B. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood, 83: 3629-3637, 1994.
81. Bseiso, A. W., Kantarjian, H. M., Guo, J. Q., Cortes, J., Talpaz, M., Koller, C., Albitar, M., Keating, M., and Arlinghaus, R. Analysis of the BCR-ABL protein in Philadelphia chromosome positive adult acute lymphocytic leukemia. Leukemia 11: 1583-1587, 1997.
82. Lee, M-S., Kantarjian, H., Talpaz, M., Freireich, E. J, Deisseroth, A., Trujillo, J. M., and Stass, S. A. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood, 79: 1920-1923, 1992.
83. Lee, M., Khouri, I., Champlin, R., Kantarjian, H., Talpaz, M., Trujillo, J., Freireich, E., Deisseroth, A., and Stass, S. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br. J. Haematol, 2: 708-714, 1992.
84. Dhingra, K., Kurzrock, R., Kantarjian, H., Baine, R., Eastman, P. S., Ku, S., Gutterman, J. U., and Talpaz, M. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia (Baltimore), 6: 754-760, 1992.
85. Kurzrock, R., Estrov, E., Kantarjian, H., and Talpaz, M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to PCR negativity. J. Clin. Oncol., in press, 1997.
86. Liu, P., Siciliano, J., Seong, D., Craig, J., Zhao, Y., de Jong, P. J., and Siciliano, M. J. Dual Alu-PCR primers and conditions for isolation of human chromosome painting probes from hybrid cells. Cancer Genet. Cytogenet., 65: 93-99, 1993.
87. Zhao, L., Kantarjian, H. M., Van Oort, J., Cork, A., Trujillo, J. M., and Liang, J. C. Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia (Baltimore), 7: 168-171, 1993.
88. Seong, D. C., Kantarjian, H., Ro, J. Y., Talpaz, M., Xu, J., Robinson, J. R., Deisseroth, A. B., Champlin, R. E., and Siciliano, M. J. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood, 86: 2343-2349, 1995.
89. Seong, D. C., Song, M. Y., Henske, E. P., Zimmerman, S. O., Champlin, R. E., Deisseroth, A., and Siciliano, M. J. Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-alu-polymerase chain reaction from a radiation hybrid. Blood, 83: 2268-2273, 1994.
90. Seong, D., Giralt, S., Fischer, H., Hayes, K., Glassman, A., Arlinghaus, R., Xu, J., Kantarjian, H., Siciliano, M., and Champlin, R. Usefulness of detection of minimal resiudal disease by "hypermetaphase" fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia. Bone Marrow Transplant., 19: 565-570, 1997.
91. Seong, D., Giralt, S., Kantarjian, H., Xu, J., Swantkowski, J., Hayes, K., Glassman, A. B., Khouri, I., Korbling, M., Thall, P., Siciliano, M. J., and Champlin, R. E. Early detection of relapse by hypermetaphase FISH after allogeneic bone marrow transplantation for chronic myeloid leukemia. J. Clin. Oncol., in press, 1997.
92. Mashal, R., Shtalrid, M., Talpaz, M., Kantarjian, H., Smith, L., Beran, M., Cork, A., Trujillo, J., Gutterman, J., and Deisseroth, A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood, 75: 180-189, 1990.
93. LeMaistre, A., Lee, M., Talpaz, M., Kantarjian, H., Deisseroth, A., Freireich, E., Trujillo, J., and Stass, S. RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood, 73: 889-891, 1989.
94. Hirsch-Ginsberg, C., LeMaistre, A. C., Kantarjian, H., Talpaz, M., Cork, A., Freireich, E. J, Trujillo, J. M., Lee, M-S., and Stass, S. A. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood, 76: 1214-1219, 1990.
95. 1 bone marrow stroma. Cancer Res., 50: 5801-5805, 1990.
96. Wetzler, M., Kurzrock, R., Lowe, D. G., Kantarjian, H., Gutterman, J. U., and Talpaz, M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood, 78: 2400-2406, 1991.
97. Wetzler, M., Kurzrock, R., Estrov, Z., Kantarjian, H., Gisslinger, H., Underbrink, M. P., and Talpaz, M. Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood, 84: 3142-3147, 1994.
98. Estrov, Z., Kurzrock, R., Wetzler, M., Kantarjian, H., Blake, M., Harris, D., Gutterman, J. U., and Talpaz, M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood, 78: 1476-1484, 1991.
99. Talpaz, M., Chernajovsky, Y., Troutman-Worden, K., Wetzler, M., Kantarjian, H., Gutterman, J. U., and Kurzrock, R. Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res., 52: 1087-1090, 1992.
100. Cortes, I., Kantarjian, H., and Talpaz, M. Association of HLA phenotype and response to interferon alpha in patients with chronic myelogenous leukemia. Blood, 86 (Suppl. 1): 438a, 1995.
101. Beran, M., Pisa, P., O'Brien, S., Kurzrock, R., Siciliano, M., Cork, A., Andersson, B. S., Kohli, V., and Kantarjian, H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res., 53: 3603-3610, 1993.